Literature DB >> 8094002

2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms.

R A Nagourney1, S S Evans, J C Messenger, Y Z Su, L M Weisenthal.   

Abstract

2-Chlorodeoxyadenosine (2-CDA) is an adenosine deaminase resistant analogue of deoxyadenosine which has shown clinical activity in human hematologic neoplasms. The exact mode of action of this drug remains the subject of investigation. We applied the Differential Staining Cytotoxicity (DiSC) assay to 50 human tumour specimens obtained from patients with a variety of hematologic malignancies to characterise the activity spectrum of 2-CDA. We evaluated the disease-specific activity of this agent in vitro and compared its relative cytotoxicity with that of other antineoplastic agents in current clinical use. Comparisons were conducted against nitrogen mustard, doxorubicin, vincristine and cytosine arabinoside. Our results indicate that 2-CDA has activity in myeloid and many lymphoid neoplasms but that multiple myeloma specimens reveal significant resistance. Cross resistance studies reveal a correlation between 2-CDA and the alkylator nitrogen mustard but no correlation between 2-CDA and doxorubicin, vincristine nor cytosine arabinoside. The results suggest 2-CDA activity in many human hematologic neoplasms with the clear exception of multiple myeloma and further suggest a relationship between this agent and alkylators of the mustard class. The DiSC assay may provide useful insights in the pre-clinical evaluation of new antineoplastic drugs and may help to elucidate drug activities and mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094002      PMCID: PMC1968239          DOI: 10.1038/bjc.1993.3

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis.

Authors:  B Lathan; M von Tettau; K Verpoort; V Diehl
Journal:  Haematol Blood Transfus       Date:  1990

2.  2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.

Authors:  L D Piro; C J Carrera; E Beutler; D A Carson
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

3.  Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells.

Authors:  J Griffig; R Koob; R L Blakley
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

4.  Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo.

Authors:  C J Carrera; H Yamanaka; L D Piro; M Lotz; D A Carson
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

5.  Induction of DNA double-strand breaks in Chinese hamster V79 cells by 2-chlorodeoxyadenosine.

Authors:  K Tanabe; W Hiraoka; M Kuwabara; F Sato; A Matsuda; T Ueda
Journal:  Chem Biol Interact       Date:  1989       Impact factor: 5.192

6.  Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial.

Authors:  A F Gazdar; S M Steinberg; E K Russell; R I Linnoila; H K Oie; B C Ghosh; J D Cotelingam; B E Johnson; J D Minna; D C Ihde
Journal:  J Natl Cancer Inst       Date:  1990-01-17       Impact factor: 13.506

7.  2-Chlorodeoxyadenosine treatment of low-grade lymphomas.

Authors:  A C Kay; A Saven; C J Carrera; D A Carson; D Thurston; E Beutler; L D Piro
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

8.  Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta.

Authors:  P Hentosh; R Koob; R L Blakley
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

9.  In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations.

Authors:  U Tidefelt; B Sundman-Engberg; A S Rhedin; C Paul
Journal:  Eur J Haematol       Date:  1989-11       Impact factor: 2.997

10.  Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.

Authors:  L D Piro; C J Carrera; D A Carson; E Beutler
Journal:  N Engl J Med       Date:  1990-04-19       Impact factor: 91.245

View more
  7 in total

Review 1.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

2.  Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.

Authors:  Bo Cai; Shuiliang Wang; Jingcao Huang; Choon-Kee Lee; Chunji Gao; Bolin Liu
Journal:  Am J Transl Res       Date:  2013-01-21       Impact factor: 4.060

Review 3.  Precision medicine for cancer with next-generation functional diagnostics.

Authors:  Adam A Friedman; Anthony Letai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Cancer       Date:  2015-11-05       Impact factor: 60.716

Review 4.  Ex vivo programmed cell death and the prediction of response to chemotherapy.

Authors:  Robert A Nagourney
Journal:  Curr Treat Options Oncol       Date:  2006-03

5.  Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.

Authors:  Jian Ma; Shuiliang Wang; Ming Zhao; Xin-Sheng Deng; Choon-Kee Lee; Xiao-Dan Yu; Bolin Liu
Journal:  BMC Cancer       Date:  2011-06-16       Impact factor: 4.430

6.  Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP.

Authors:  A G Bosanquet; A R Burlton; P B Bell; A L Harris
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

Authors:  S Dhar; P Nygren; K Csoka; J Botling; K Nilsson; R Larsson
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.